Royal Marsden Hospital

The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.

The Clinical Treatment Score post-5-years tool helps clinicians identify which patients are at high risk of their cancers recurring after completing five years of adjuvant hormone therapy.

A study reported this week that measuring changes in the numbers of specific circulating tumor DNA mutations can rapidly identify breast cancer patients who will have better outcomes.